BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming SVB Securities Global Biopharma Conference taking place on February 14-16, 2023. Details for the event are as follows:
SVB Securities Global Biopharma Conference | |
Date: | Tuesday, February 14th, 2023 |
Time: | 8:00 AM EST |
Webcast: | Click Here |
A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of the presentation will be available on this same website following the event.
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
Galecto, Inc. | |
Hans Schambye, CEO | |
Jon Freve, CFO | |
+45 70 70 52 10 | |
Investors/US | Media/EU |
Ashley R. Robinson | Sandya von der Weid |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
+1 617 430 7577 | +41 78 680 0538 |
Last Trade: | US$0.53 |
Daily Change: | -0.01 -2.73 |
Daily Volume: | 28,554 |
Market Cap: | US$14.370M |
December 21, 2023 August 15, 2023 June 20, 2023 |
Pond Technologies has developed a proprietary system that can profitably transform CO2 into valuable products. The company's carbon business focuses on absorbing greenhouse gas emissions, transforming these into...
CLICK TO LEARN MOREGreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS